Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (1568)	2/16/2006 2:48:45 PM
From: Jibacoa	Read Replies (2) \| Respond to of 3722

HEB today released the results of laboratory tests that shows that its Ampligen and Alferon are potentially useful against the H5N1 flu virus. The research indicated that Ampligen can provide cross-protection against avian flu viral mutations and can boost up to 100x the effectiveness of Tamiflu and Relenza,which are the only two drugs recognized for treating the asian flu. Other tests showed that Alferon can stimulate genes that induce the production of interferon. These results are been presented at today's American Society for Microbiology Biodefense Research Meeting in Washington, DC. HEB's stock opened with an upgap. bigcharts.marketwatch.com It is trading above its Dec.-Feb Hs with volume now up to 2,217,900 The stock needs to close above its Dec.3-Dec.4 double top at the 3.44 level in order to be able to test Oct.27 H at 3.70 <g> bigcharts.marketwatch.com The April 30 2004 H at 5.40 seems a little too far at present.<g> bigcharts.marketwatch.com And the March 2000 H at 19 is even farther up.<g> bigcharts.marketwatch.com Bernard